Results 251 to 260 of about 1,444,670 (278)

FDA okays first cardiac myosin inhibitor

Nature Biotechnology, 2022
openaire   +1 more source

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin

International Journal of Toxicology
Aficamten (CK-3773274) is a cardiac myosin inhibitor in development for the treatment of hypertrophic cardiomyopathy (HCM), a commonly inherited heart condition often characterized as a disease of the sarcomere. Aficamten reduces pathologic cardiac hypercontractility by selectively binding to an allosteric site on cardiac myosin.
Michael K. Pugsley, Darren T. Hwee, Brett R. Winters, Jingying Wang, Eva R. Chin, Bradley P. Morgan, Fady I. Malik   +6 more
openaire   +2 more sources

Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology, 2022
openaire   +1 more source

Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential

Expert Opinion on Investigational Drugs, 2023
Shiavax J Rao, Beani Forst, Amreen K Kanwal, Arjun Kanwal, Wilbert S. Aronow, Srihari S Naidu   +5 more
openaire   +2 more sources

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Journal of the American Heart Association, 2022
Ahmad Masri, Iacopo Olivotto
exaly  

Update on Cardiac Myosin Inhibitors and Potential Role in Treating Obstructive Hypertrophic Cardiomyopathy

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2023
Michael J, Litt, Sharlene M, Day
openaire   +2 more sources

Cardiac myosin inhibitors in the treatment of hypertrophic cardiomyopathy (literature review)

Pharmateca, 2023
L.V. Kononenko Kononenko, G.G. Taradin Taradin, G.A. Ignatenko Ignatenko   +2 more
openaire   +1 more source

Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin

Proceedings of the National Academy of Sciences of the United States of America, 2018
Osha Roopnarine, David D Thomas, John A Rohde   +2 more
exaly  

Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers

Proceedings of the National Academy of Sciences of the United States of America, 2018
Joshua M Gorham, Makenna Morck, Eric M Green   +2 more
exaly  

Cardiac myosin inhibitors for the treatment of obstructive and non-obstructive HCM

Nature Reviews Cardiology
openaire   +2 more sources